CA Stock MarketDetailed Quotes
CTX Crescita Therapeutics Inc
- 0.660
- -0.010-1.49%
15min DelayMarket Closed Aug 30 16:00 ET
12.79MMarket Cap-4400P/E (TTM)
0.660High0.650Low17.55KVolume0.650Open0.670Pre Close11.54KTurnover0.72052wk High0.10%Turnover Ratio19.38MShares0.36052wk Low-0.15EPS TTM11.22MFloat Cap2.000Historical HighLossP/E (Static)17.00MShs Float0.350Historical Low-0.1EPS LYR1.49%Amplitude--Dividend TTM0.74P/B1Lot Size--Div YieldTTM
Crescita Therapeutics Inc Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 575.31%547K | -82.26%378K | 303.53%2.08M | 88.22%-261K | -72.59%125K | 1.25%81K | 223.37%2.13M | 36.13%-1.02M | -372.28%-2.22M | 341.27%456K |
| Net income from continuing operations | -229.54%-926K | -129.30%-626K | -330.39%-1.99M | -112.73%-150K | -757.44%-1.28M | -659.46%-281K | 42.41%-273K | 178.01%862K | 24.92%1.18M | 121.67%195K |
| Operating gains losses | ---2K | 80.00%9K | -96.59%6K | -80.39%10K | -1,000.00%-9K | ---- | -58.33%5K | 2,300.00%176K | --51K | --1K |
| Depreciation and amortization | -18.93%304K | 2.67%385K | 2.38%1.51M | 0.53%379K | 5.31%377K | 1.35%375K | 2.46%375K | 6.67%1.47M | 8.65%377K | 2.29%358K |
| Asset impairment expenditure | -37.21%81K | 62.79%70K | -16.73%438K | -12.71%158K | -36.47%108K | 12.17%129K | -28.33%43K | 19.55%526K | 13.13%181K | 6.25%170K |
| Remuneration paid in stock | -16.92%54K | -4.55%21K | -62.90%82K | -143.75%-21K | -23.81%16K | -14.47%65K | -71.05%22K | -18.75%221K | -60.98%48K | -46.15%21K |
| Deferred tax | --0 | --0 | 199.56%456K | 143.01%197K | --0 | --93K | --166K | -577.08%-458K | ---458K | --0 |
| Other non cashItems | -328.57%-48K | -276.60%-177K | 68.93%-32K | 124.32%45K | -466.67%-51K | 310.00%21K | -146.53%-47K | -239.19%-103K | -372.06%-185K | 85.71%-9K |
| Change In working capital | 437.69%1.08M | -62.17%696K | 143.23%1.61M | 74.20%-879K | 445.00%966K | 41.21%-321K | 255.21%1.84M | -35.34%-3.72M | -55.00%-3.41M | -224.44%-280K |
| -Change in receivables | 140.04%1.28M | -131.30%-601K | 245.04%3.54M | 88.57%-274K | 2,822.00%1.36M | 547.06%532K | 1,423.81%1.92M | -16.41%-2.44M | -1.74%-2.4M | -111.85%-50K |
| -Change in inventory | 6,700.00%66K | 568.46%996K | 48.48%-917K | 52.87%-394K | -195.59%-671K | 98.94%-1K | 123.92%149K | -29.45%-1.78M | -416.67%-836K | 78.21%-227K |
| -Change in payables and accrued expense | 92.52%-75K | 216.00%348K | -654.74%-1.29M | -50.55%-408K | 1,866.67%424K | -177.84%-1M | -133.78%-300K | -76.64%232K | -179.38%-271K | -102.59%-24K |
| -Change in other current assets | -221.85%-184K | -166.20%-47K | -0.73%271K | 103.09%197K | -804.76%-148K | 439.29%151K | -44.09%71K | 202.25%273K | 1,177.78%97K | 125.30%21K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 575.31%547K | -82.26%378K | 303.53%2.08M | 88.22%-261K | -72.59%125K | 1.25%81K | 223.37%2.13M | 36.13%-1.02M | -372.28%-2.22M | 341.27%456K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -912K | 0 | 54.14%-133K | -41.89%-105K | -1,300.00%-28K | 0 | 0 | 65.72%-290K | 66.67%-74K | 99.66%-2K |
| Net PPE purchase and sale | ---912K | --0 | 41.92%-133K | -707.69%-105K | -1,300.00%-28K | --0 | --0 | 33.82%-229K | 94.14%-13K | 97.53%-2K |
| Net business purchase and sale | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---61K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---912K | --0 | 54.14%-133K | -41.89%-105K | -1,300.00%-28K | --0 | --0 | 65.72%-290K | 66.67%-74K | 99.66%-2K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -56.44%-158K | -138.38%-236K | 57.64%-782K | -16.74%-258K | -19.12%-324K | 91.48%-101K | 41.07%-99K | -269.20%-1.85M | -13.92%-221K | -161.54%-272K |
| Net issuance payments of debt | -8.91%-110K | -9.09%-108K | 70.28%-408K | -6.06%-105K | -11.96%-103K | 90.74%-101K | -8.79%-99K | -293.41%-1.37M | -11.24%-99K | -12.20%-92K |
| Net common stock issuance | ---48K | ---78K | 8.39%-393K | -112.50%-153K | -33.33%-240K | --0 | --0 | -324.75%-429K | -30.91%-72K | -718.18%-180K |
| Proceeds from stock option exercised by employees | ---- | ---- | 216.67%19K | --0 | --19K | ---- | ---- | --6K | --0 | --0 |
| Net other financing activities | ---- | ---50K | ---- | ---- | ---- | ---- | ---- | 0.00%-50K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -56.44%-158K | -138.38%-236K | 57.64%-782K | -16.74%-258K | -19.12%-324K | 91.48%-101K | 41.07%-99K | -269.20%-1.85M | -13.92%-221K | -161.54%-272K |
| Net cash flow | ||||||||||
| Beginning cash position | -7.24%9.53M | 13.92%9.39M | -27.30%8.24M | -6.68%10.02M | -2.63%10.23M | -12.49%10.28M | -27.30%8.24M | -20.66%11.33M | -12.24%10.74M | -19.73%10.5M |
| Current changes in cash | -2,515.00%-523K | -93.01%142K | 136.79%1.16M | 75.14%-624K | -224.73%-227K | 98.43%-20K | 355.61%2.03M | -7.24%-3.16M | -183.62%-2.51M | 120.82%182K |
| Effect of exchange rate changes | 113.79%4K | -20.00%4K | -122.22%-14K | -220.00%-12K | -59.26%22K | -185.29%-29K | 114.29%5K | 1,000.00%63K | 150.00%10K | 100.00%54K |
| End cash Position | -11.87%9.01M | -7.24%9.53M | 13.92%9.39M | 13.92%9.39M | -6.68%10.02M | -2.63%10.23M | -12.49%10.28M | -27.30%8.24M | -27.30%8.24M | -12.24%10.74M |
| Free cash from | -550.62%-365K | -82.26%378K | 255.56%1.94M | 83.57%-366K | -78.63%97K | 191.01%81K | 247.07%2.13M | 35.72%-1.25M | -222.43%-2.23M | 268.15%454K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Latest Price
% Chg